Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shubham Pant

Showing results (51-60 of 181) with videos related to

Pageof 19
Sort By:
Investigational New Drugs|March 26, 2013
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumorsShubham Pant, Howard A Burris, Kathleen Moore, et al.
Investigational New Drugs|August 19, 2017
Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignanciesXiaofei Zhou, John Nemunaitis, Shubham Pant, et al.
Surgical Oncology|January 7, 2022
Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinomaElena Panettieri, Harufumi Maki, Bradford J Kim, et al.
American Journal of Clinical Oncology|July 29, 2014
Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With BevacizumabShubham Pant, Ludmila K Martin, Susan Geyer, et al.
JCO Precision Oncology|June 3, 2026
ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into ResponseSupriya Peshin, Fen Saj, Pashtoon M Kasi, et al.
Investigational New Drugs|March 9, 2021
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumorsAnalia Azaro, Christophe Massard, William D Tap, et al.
Investigational New Drugs|August 31, 2017
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignanciesXiaofei Zhou, Shubham Pant, John Nemunaitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2022
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based ChemotherapySunyoung Lee, Rachna T Shroff, Shalini Makawita, et al.
Molecular Cancer Therapeutics|June 20, 2023
Discordance of HER2 Expression and/or Amplification on Repeat TestingTimothy P DiPeri, Kathleen Kong, Kaushik Varadarajan, et al.
Cancers|June 26, 2026
Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract CancerMakenna A Smack, Jane E Rogers, Lianchun Xiao, et al.
Pageof 19

Showing results (51-60 of 181) with videos related to

Sort By:
Pageof 19
Investigational New Drugs|March 26, 2013
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumorsShubham Pant, Howard A Burris, Kathleen Moore, et al.
Investigational New Drugs|August 19, 2017
Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignanciesXiaofei Zhou, John Nemunaitis, Shubham Pant, et al.
Surgical Oncology|January 7, 2022
Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinomaElena Panettieri, Harufumi Maki, Bradford J Kim, et al.
American Journal of Clinical Oncology|July 29, 2014
Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With BevacizumabShubham Pant, Ludmila K Martin, Susan Geyer, et al.
JCO Precision Oncology|June 3, 2026
ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into ResponseSupriya Peshin, Fen Saj, Pashtoon M Kasi, et al.
Investigational New Drugs|March 9, 2021
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumorsAnalia Azaro, Christophe Massard, William D Tap, et al.
Investigational New Drugs|August 31, 2017
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignanciesXiaofei Zhou, Shubham Pant, John Nemunaitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2022
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based ChemotherapySunyoung Lee, Rachna T Shroff, Shalini Makawita, et al.
Molecular Cancer Therapeutics|June 20, 2023
Discordance of HER2 Expression and/or Amplification on Repeat TestingTimothy P DiPeri, Kathleen Kong, Kaushik Varadarajan, et al.
Cancers|June 26, 2026
Durvalumab with Gemcitabine and Oxaliplatin in Advanced Biliary Tract CancerMakenna A Smack, Jane E Rogers, Lianchun Xiao, et al.
Pageof 19